Life quality among psoriasis patients based on Dermatology Life Quality Index evaluation and its association with psoriasis severity in China: a cross-sectional study

References

• Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021;397(10281):1–10. doi: 10.1016/S0140-6736(20)32549-6.
   PubMed Web of Science ®Google Scholar
• Park SY, Kim KH. What factors influence on dermatology-related life quality of psoriasis patients in South Korea? Int J Environ Res Public Health. 2021;18(7):3624.
   PubMed Web of Science ®Google Scholar
• Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–212. doi: 10.1111/jdv.13854.
   PubMed Web of Science ®Google Scholar
• Wei L, Chen S, Zhang Z, et al. Prevalence of tobacco smoking and its association with disease severity among patients with psoriasis in China: a cross-sectional study. Front Med. 2022;9:883458. doi: 10.3389/fmed.2022.883458.
   Web of Science ®Google Scholar
• Sondermann W, Schreiber A, Korber A, et al. Psychosocial burden and body mass index are associated with dermatology-related quality of life in psoriasis patients. Eur J Dermatol. 2020;30(2):140–147. doi: 10.1684/ejd.2020.3755.
   PubMed Web of Science ®Google Scholar
• Silva MF, Fortes MR, Miot LD, et al. Psoriasis: correlation between severity index (PASI) and quality of life index (DLQI) in patients assessed before and after systemic treatment. An Bras Dermatol. 2013;88(5):760–763. doi: 10.1590/abd1806-4841.20132052.
   PubMed Web of Science ®Google Scholar
• Dave R, Alkeswani A. An overview of biologics for psoriasis. J Drugs Dermatol. 2021;20(11):1246–1247. doi: 10.36849/jdd.6040.
   PubMed Web of Science ®Google Scholar
• Silfvast-Kaiser A, Paek SY, Menter A. Anti-IL17 therapies for psoriasis. Expert Opin Biol Ther. 2019;19(1):45–54. doi: 10.1080/14712598.2019.1555235.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Chenoweth A, Crescioli S, et al. Antibodies to watch in 2022. MAbs. 2022;14(1):2014296. doi: 10.1080/19420862.2021.2014296.
   PubMed Web of Science ®Google Scholar
• Valenti M, Costanzo A. Efficacy and safety of switching psoriatic patients to bimekizumab: new evidence from clinical trials. Br J Dermatol. 2023;188(3):316–317. doi: 10.1093/bjd/ljac133.
   PubMed Web of Science ®Google Scholar
• Solmaz N, Ilhan N, Bulut HM. The effect of illness perception on life quality in psoriasis patients. Psychol Health Med. 2021;26(8):955–967. doi: 10.1080/13548506.2020.1847300.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in ­moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29–39. doi: 10.1016/j.jaad.2022.07.002.
   PubMed Web of Science ®Google Scholar
• Kiltz U, Sfikakis PP, Gaffney K, et al. Secukinumab use in patients with moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis in real-world setting in Europe: baseline data from SERENA study. Adv Ther. 2020;37(6):2865–2883. doi: 10.1007/s12325-020-01352-8.
   PubMed Web of Science ®Google Scholar
• Poor AK, Brodszky V, Pentek M, et al. Is the DLQI appropriate for medical decision-making in psoriasis patients? Arch Dermatol Res. 2018;310(1):47–55. doi: 10.1007/s00403-017-1794-4.
   PubMed Web of Science ®Google Scholar
• Nasreen S, Ahmed I, Effendi S. Frequency and magnitude of anxiety and depression in patients with psoriasis vulgaris. J Coll Physicians Surg Pak. 2008;18(7):397–400.
   PubMed Web of Science ®Google Scholar
• Mazzotti E, Picardi A, Sampogna F, et al. Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis. Br J Dermatol. 2003;149(2):318–322. doi: 10.1046/j.1365-2133.2003.05378.x.
   PubMed Web of Science ®Google Scholar
• Khan JM, Rathore MU, Tahir M, et al. Dermatology Life Quality Index in patients of psoriasis and its correlation with severity of disease. J Ayub Med Coll Abbottabad. 2020;32(1):64–67.
   PubMedGoogle Scholar
• Psoriasis Group of the Chinese Medical Association DaVB. Expert consensus on the treatment of psoriasis in China (2014 edition). Chin J Dermatol. 2014;47(3):213–215.
   Google Scholar
• Sendrasoa FA, Razanakoto NH, Ratovonjanahary V, et al. Quality of life in patients with psoriasis seen in the department of dermatology, Antananarivo, Madagascar. Biomed Res Int. 2020;2020:9292163. doi: 10.1155/2020/9292163.
   PubMed Web of Science ®Google Scholar
• Kouris A, Platsidaki E, Kouskoukis C, et al. Psychological parameters of psoriasis. Psychiatriki. 2017;28(1):54–59. doi: 10.22365/jpsych.2017.281.54.
   PubMedGoogle Scholar
• Tadros A, Vergou T, Stratigos AJ, et al. Psoriasis: is it the tip of the iceberg for the quality of life of patients and their families? J Eur Acad Dermatol Venereol. 2011;25(11):1282–1287. doi: 10.1111/j.1468-3083.2010.03965.x.
   PubMed Web of Science ®Google Scholar
• Imafuku S, Kanai Y, Murotani K, et al. Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: results from the ProLOGUE study. J Dermatol Sci. 2021;101(3):185–193. doi: 10.1016/j.jdermsci.2021.01.002.
   PubMed Web of Science ®Google Scholar
• Hagg D, Sundstrom A, Eriksson M, et al. Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI). J Eur Acad Dermatol Venereol. 2015;29(3):452–456. doi: 10.1111/jdv.12576.
   PubMed Web of Science ®Google Scholar
• Lukmanji A, Basmadjian RB, Vallerand IA, et al. Risk of depression in patients with psoriatic disease: a systematic review and meta-analysis. J Cutan Med Surg. 2021;25(3):257–270. doi: 10.1177/1203475420977477.
   PubMed Web of Science ®Google Scholar
• Chan B, Hales B, Shear N, et al. Work-related lost ­productivity and its economic impact on Canadian ­patients with moderate to severe psoriasis. J Cutan Med Surg. 2009;13(4):192–197. doi: 10.2310/7750.2009.08068.
   PubMed Web of Science ®Google Scholar
• Stein KR, Pearce DJ, Feldman SR. The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg. 2005;24(1):52–57. doi: 10.1016/j.sder.2005.01.004.
   PubMed Web of Science ®Google Scholar
• Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333–337. doi: 10.1111/jdv.12106.
   PubMed Web of Science ®Google Scholar
• Sojevic Timotijevic Z, Majcan P, Trajkovic G, et al. The impact of changes in Psoriasis Area and Severity Index by body region on quality of life in patients with psoriasis. Acta Dermatovenerol Croat. 2017;25(3):215–222.
   PubMed Web of Science ®Google Scholar
• Narcisi A, Valenti M, Cortese A, et al. Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: a single-center retrospective comparative study. Dermatol Ther. 2022;35(2):e15228. doi: 10.1111/dth.15228.
   PubMed Web of Science ®Google Scholar
• Yi OS, Huan KY, Har LC, et al. Genital psoriasis: a prospective, observational, single-centre study on prevalence, clinical features, risk factors, and its impact on quality of life and sexual health. Indian J Dermatol. 2022;67(2):205. doi: 10.4103/ijd.ijd_754_21.
   PubMed Web of Science ®Google Scholar
• Ibba L, Gargiulo L, Alfano A, et al. Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study. J Dermatolog Treat. 2023;34(1):2199108. doi: 10.1080/09546634.2023.2199108.
   PubMed Web of Science ®Google Scholar
• Pollo CF, Miot HA, Matos TDS, et al. Prevalence and factors associated with depression and anxiety in patients with psoriasis. J Clin Nurs. 2021;30(3–4):572–580. doi: 10.1111/jocn.15577.
   PubMed Web of Science ®Google Scholar
• Jung S, Lee SM, Suh D, et al. The association of socioeconomic and clinical characteristics with health-related quality of life in patients with psoriasis: a cross-sectional study. Health Qual Life Outcomes. 2018;16(1):180. doi: 10.1186/s12955-018-1007-7.
   PubMedGoogle Scholar
• Zachariae R, Zachariae H, Blomqvist K, et al. Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol. 2002;146(6):1006–1016. doi: 10.1046/j.1365-2133.2002.04742.x.
   PubMed Web of Science ®Google Scholar
• Do anti-psoriatic drugs work better in women than men? Br J Dermatol. 2021;185(6):e200–e213.
   PubMedGoogle Scholar
• Budu-Aggrey A, Brumpton B, Tyrrell J, et al. Evidence of a causal relationship between body mass index and psoriasis: a Mendelian randomization study. PLoS Med. 2019;16(1):e1002739. doi: 10.1371/journal.pmed.1002739.
   PubMed Web of Science ®Google Scholar
• Jensen P, Skov L. Psoriasis and obesity. Dermatology. 2016;232(6):633–639. doi: 10.1159/000455840.
   PubMed Web of Science ®Google Scholar
• Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2020;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
   PubMedGoogle Scholar
• Dowlatshahi EA, van der Voort EA, Arends LR, et al. Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2013;169(2):266–282. doi: 10.1111/bjd.12355.
   PubMed Web of Science ®Google Scholar